Otsuka Holdings Co., Ltd.: Leukemia, Myeloid, Acute trials

The registry lists 19 Leukemia, Myeloid, Acute studies with Otsuka Holdings Co., Ltd. as lead sponsor. 4 are open to participants now and 9 have results posted.

Phase 1 12Phase 2 5Phase 3 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic ImpairmentRecruitingNCT04953910Phase 1
• Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal ImpairmentRecruitingNCT04953897Phase 1
• A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingNCT04256317Phase 2/3
• A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)Enrolling by invitationNCT04093570Phase 2
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLCompletedNCT03306264Phase 3Results posted
• Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid LeukemiaCompletedNCT02920008Phase 3Results posted
• SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionCompletedNCT02348489Phase 3Results posted
• Phase 1 Study of SGI-110 in Patients With Acute Myeloid LeukemiaCompletedNCT02293993Phase 1Results posted
• A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid LeukemiaCompletedNCT01961882Phase 2Results posted
• Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)CompletedNCT01475370Phase 1Results posted
• A Phase I Study of OCV-501 in Acute Myeloid Leukemia PatientsCompletedNCT01440920Phase 1Results posted
• Phase I Study of OPB-51602 in Patients With Hematologic MalignanciesCompletedNCT01344876Phase 1Results posted
• SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)CompletedNCT01261312Phase 1/2Results posted
• A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT05883956Phase 3
• Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)Active, not recruitingNCT04657081Phase 1/2
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsTerminatedNCT04637009Phase 1
• A Study of TAS1440 With ATRA in Subjects With r/r AMLTerminatedNCT04282668Phase 1
• A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)TerminatedNCT04155580Phase 1
• Effect of Food on Blood Levels of ASTX727CompletedNCT03813186Phase 1